(LNTH) Lantheus Holdings - Overview
Stock: Diagnostic, Therapeutic, Imaging, Prostate, Cardiovascular
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 50.5% |
| Relative Tail Risk | -12.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.39 |
| Alpha | -37.85 |
| Character TTM | |
|---|---|
| Beta | 0.476 |
| Beta Downside | 0.366 |
| Drawdowns 3y | |
|---|---|
| Max DD | 59.46% |
| CAGR/Max DD | 0.06 |
Description: LNTH Lantheus Holdings January 09, 2026
Lantheus Holdings (NASDAQ: LNTH) is a U.S.-based developer and commercializer of diagnostic and therapeutic radiopharmaceuticals and imaging agents that support clinicians in cardiology, oncology, neurology and nuclear medicine.
Core marketed products include DEFINITY (ultrasound contrast for echocardiography), TechneLite (technetium-99m generator), Xenon-133 (pulmonary function), Neurolite (stroke imaging), Cardiolite (myocardial perfusion), and PYLARIFY (F-18 PSMA PET agent for prostate cancer). The company also offers AI-driven software such as Automated Bone Scan Index, aPROMISE, and PYLARIFY AI to quantify imaging data.
Pipeline highlights (as of Q4 2024) feature 1095 (I-131 PSMA therapy), PNT2002 (α-emitting radiotherapy for metastatic castration-resistant prostate cancer), PNT2003 (SSTR-targeted therapy for neuroendocrine tumors), MK-6240 (F-18 Tau PET for Alzheimer’s), and several novel GRPR- and FAP-targeted agents (LNTH-2401/2402/2403/2404, LNTH-1363S). These programs align with the broader industry shift toward theranostics-combining diagnostics and targeted radionuclide therapy.
Financially, LNTH reported FY 2023 revenue of $382 million, a 12% YoY increase driven primarily by growth in PYLARIFY sales (up ~45%). The balance sheet showed $210 million of cash and equivalents, providing runway for continued R&D and potential strategic acquisitions. The company’s gross margin averaged 71%, reflecting the high-value nature of radiopharmaceuticals.
Key sector drivers include rising global demand for precision oncology imaging (projected CAGR ≈ 9% through 2030), expanding reimbursement for PSMA-targeted PET scans, and increasing adoption of AI tools to improve diagnostic workflow efficiency.
Strategic collaborations with GE Healthcare (distribution), Regeneron (co-development), and Ratio Therapeutics (early-stage pipelines) broaden market access and de-risk development timelines.
For analysts looking to deepen their valuation framework, ValueRay’s detailed cash-flow and scenario-analysis tools can help quantify the upside potential of LNTH’s theranostic pipeline.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 167.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.18 > 0.02 and ΔFCF/TA -4.20 > 1.0 |
| NWC/Revenue: 37.90% < 20% (prev 34.18%; Δ 3.71% < -1%) |
| CFO/TA 0.20 > 3% & CFO 455.4m > Net Income 167.7m |
| Net Debt (237.4m) to EBITDA (326.9m): 0.73 < 3 |
| Current Ratio: 2.67 > 1.5 & < 3 |
| Outstanding Shares: last quarter (67.7m) vs 12m ago -7.39% < -2% |
| Gross Margin: 62.23% > 18% (prev 0.65%; Δ 6158 % > 0.5%) |
| Asset Turnover: 70.55% > 50% (prev 73.03%; Δ -2.48% > 0%) |
| Interest Coverage Ratio: 13.31 > 6 (EBITDA TTM 326.9m / Interest Expense TTM 19.7m) |
Altman Z'' 3.94
| A: 0.25 (Total Current Assets 925.1m - Total Current Liabilities 346.8m) / Total Assets 2.28b |
| B: 0.27 (Retained Earnings 625.4m / Total Assets 2.28b) |
| C: 0.12 (EBIT TTM 262.4m / Avg Total Assets 2.16b) |
| D: 0.54 (Book Value of Equity 624.5m / Total Liabilities 1.16b) |
| Altman-Z'' Score: 3.94 = AA |
Beneish M -2.41
| DSRI: 1.14 (Receivables 383.3m/329.3m, Revenue 1.53b/1.50b) |
| GMI: 1.05 (GM 62.23% / 65.44%) |
| AQI: 1.96 (AQ_t 0.52 / AQ_t-1 0.27) |
| SGI: 1.02 (Revenue 1.53b / 1.50b) |
| TATA: -0.13 (NI 167.7m - CFO 455.4m) / TA 2.28b) |
| Beneish M-Score: -2.41 (Cap -4..+1) = BBB |
What is the price of LNTH shares?
Over the past week, the price has changed by -3.03%, over one month by -6.87%, over three months by +20.86% and over the past year by -28.61%.
Is LNTH a buy, sell or hold?
- StrongBuy: 9
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the LNTH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 83.5 | 28.6% |
| Analysts Target Price | 83.5 | 28.6% |
| ValueRay Target Price | 63.3 | -2.4% |
LNTH Fundamental Data Overview February 03, 2026
P/E Forward = 12.0627
P/S = 2.9819
P/B = 3.9507
P/EG = 0.61
Revenue TTM = 1.53b USD
EBIT TTM = 262.4m USD
EBITDA TTM = 326.9m USD
Long Term Debt = 567.9m USD (from longTermDebt, last quarter)
Short Term Debt = 871.0k USD (from shortTermDebt, last quarter)
Debt = 619.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 237.4m USD (from netDebt column, last quarter)
Enterprise Value = 4.79b USD (4.55b + Debt 619.4m - CCE 382.0m)
Interest Coverage Ratio = 13.31 (Ebit TTM 262.4m / Interest Expense TTM 19.7m)
EV/FCF = 11.78x (Enterprise Value 4.79b / FCF TTM 406.3m)
FCF Yield = 8.49% (FCF TTM 406.3m / Enterprise Value 4.79b)
FCF Margin = 26.62% (FCF TTM 406.3m / Revenue TTM 1.53b)
Net Margin = 10.99% (Net Income TTM 167.7m / Revenue TTM 1.53b)
Gross Margin = 62.23% ((Revenue TTM 1.53b - Cost of Revenue TTM 576.3m) / Revenue TTM)
Gross Margin QoQ = 57.91% (prev 63.75%)
Tobins Q-Ratio = 2.10 (Enterprise Value 4.79b / Total Assets 2.28b)
Interest Expense / Debt = 0.80% (Interest Expense 4.95m / Debt 619.4m)
Taxrate = 34.47% (14.6m / 42.4m)
NOPAT = 171.9m (EBIT 262.4m * (1 - 34.47%))
Current Ratio = 2.67 (Total Current Assets 925.1m / Total Current Liabilities 346.8m)
Debt / Equity = 0.55 (Debt 619.4m / totalStockholderEquity, last quarter 1.12b)
Debt / EBITDA = 0.73 (Net Debt 237.4m / EBITDA 326.9m)
Debt / FCF = 0.58 (Net Debt 237.4m / FCF TTM 406.3m)
Total Stockholder Equity = 1.13b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.75% (Net Income 167.7m / Total Assets 2.28b)
RoE = 14.78% (Net Income TTM 167.7m / Total Stockholder Equity 1.13b)
RoCE = 15.41% (EBIT 262.4m / Capital Employed (Equity 1.13b + L.T.Debt 567.9m))
RoIC = 10.10% (NOPAT 171.9m / Invested Capital 1.70b)
WACC = 6.81% (E(4.55b)/V(5.17b) * Re(7.67%) + D(619.4m)/V(5.17b) * Rd(0.80%) * (1-Tc(0.34)))
Discount Rate = 7.67% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.75%
[DCF Debug] Terminal Value 85.23% ; FCFF base≈424.6m ; Y1≈523.7m ; Y5≈891.9m
Fair Price DCF = 294.9 (EV 19.79b - Net Debt 237.4m = Equity 19.55b / Shares 66.3m; r=6.81% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -13.42 | EPS CAGR: -41.77% | SUE: -4.0 | # QB: 0
Revenue Correlation: 85.99 | Revenue CAGR: 33.61% | SUE: 2.21 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.21 | Chg30d=+0.015 | Revisions Net=+2 | Analysts=8
EPS next Year (2026-12-31): EPS=5.54 | Chg30d=+0.030 | Revisions Net=-1 | Growth EPS=-0.5% | Growth Revenue=-0.2%